TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04481204

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT05000866

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug use module
Description: The substance use module is administered after step 5 of CHTC and prior to the delivery of rapid HIV-test results. The couple was first asked to fill in a calendar for the past 30 days, indicating each day on which either member used drugs or consumed alcohol. Completion of the calendar is done through an ACCESS database to facilitate remote intervention delivery. After completion of the calendar, the HIV tester asked a series of debriefing questions designed to elicit the couples' perspective on their use, establish the couple's goals and limits for drug use, and make plans to achieve these goals.
Study: NCT01345422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wii Balance Board
Description: Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
Study: NCT05773716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2\~6-second and a 2\~6-second relaxation following each one.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pelvic floor muscle training
Description: Participants will receive daily pelvic floor muscle training for 6 consecutive weeks. In specific, they will be instructed to perform 3 training sessions (morning, afternoon and evening) per day with an emptied bladder in a relaxed state. During each session, 10 muscle stretches are required with each contraction duration of 2\~6-second and a 2\~6-second relaxation following each one.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Participants will also receive electroacupuncture at bilateral Zhongliao (BL33), Huiyang (BL35), Zhongji (CV3), Guanyuan (CV4) and Dahe (KI12). During each therapy session, the electroacupuncture stimulation of acupoints in the abdomen and sacral regions will last for 30 minutes in total (15 minutes for each region) with a continuous wave of 50 Hz and a current intensity of 1 to 5 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 3 treatment sessions per week (ideally every other day) for 6 consecutive weeks, 18 sessions in total.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham electroacupuncture will be carried out with pragmatic placebo needles on the same acupoints in the experimental group. Procedures, electrode placements, and other treatment settings will also stay the same but with no electrical stimulation output.
Study: NCT06646172

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse thoracic muscle plane block (TTMPB) using liposomal bupivacaine and bupivacaine mixture
Description: Liposomal bupivacaine and bupivacaine mixture were used for transverse thoracic muscle plane block (TTMPB) in experimental group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse thoracic muscle plane block (TTMPB) using bupivacaine hydrochloride
Description: Bupivacaine hydrochloride was used for transverse thoracic muscle plane block (TTMPB) in active control group.
Study: NCT04885075

Intervention type: DRUG
Group type: OTHER
Intervention: IV diazepam
Description: inj.diazepam 0.2mg/kg/dose stat

Intervention type: DRUG
Group type: OTHER
Intervention: I/N Midazolam
Description: intranasal midazolam 0.2mg/kg/dose stat
Study: NCT05420961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Study: NCT05126550

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccine (Vero cell) inactivated
Description: Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 vaccine (Vero cell) inactivated
Description: Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with Vaksinasi Gotong Royong (mutual cooperation vaccination program)
Study: NCT05868460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity laser
Description: patients will receive Nd: YAG with wavelength 1064 nm, peak power 3KW, energy density 360-1780 mJ/cm2, a short duration 120-150 micro sec, a mean power 10.5 W, a low frequency 10-40 HZ, a duty cycle of 0.1%, a probe diameter of 0.5 cm and spot size of 0.2 cm2. The treatment will be applied into 3 phases in each session. In addition to the traditional physical therapy exercise program (passive and active ROM exercises, stretching and strengthening exercises) for 20 minutes, total session time is 35 minutes, 3 days/ week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physical therapy exercise program
Description: passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional physical therapy exercise program
Description: passive and active ROM exercises, stretching and strengthening exercises for 35 minutes, 3 days/ week for 4 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo High intensity laser
Description: patients will receive placebo HILT including the same treatment as in group A but the laser device will be turned off.
Study: NCT05420961

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV15
Description: Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F, and 4 μg of 6B in each 0.5 mL sterile suspension

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal 23-valent vaccine with 25 μg of each of the PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study: NCT05366179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.B7-H3T cells infusion
Description: The Chimeric Antigen Receptors (CAR).B7-H3T cells will be administered via intraventricular infusion up to 3 weekly infusions. A suspension of T cells infusion is given, over 5-10 minutes, via a Rickham catheter and will be followed by a normal-saline flush.~Dose escalation will be performed considering the dose limiting toxicities (DLTs) listed in the protocol. Six doses will be explored. The starting dose will be 2 × 10\^6 transduced cells/infusion (Dose Level (DL) 1) and will enroll at least 3 subjects. If there are no dose DLTs within 4 weeks of the third cellular product administration in the first 3 subjects, then the next cohort will evaluate 5 × 10\^6 transduced cells/infusion (DL2).
Study: NCT05959577

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapled hemorrhoidopexy with anoplasty
Description: The patients who meet the inclusion and exclusion criteria in this group will undergo Stapled hemorrhoidopexy with anoplasty.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ferguson hemorrhoidectomy
Description: Ferguson hemorrhoidectomy
Study: NCT06210659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Theory of Planned Behavior Based Training Program
Description: Theory of Planned Behavior Based Training Program will be implemented. The training program will consist of 4 sessions. First session; It will consist of the definition, symptoms and treatment approaches of primary dysmenorrhea. Content of the second session; It will consist of lifestyle interventions in dysmenorrhea. Content of the third session; It will consist of the importance of physical activity in primary dysmenorrhea. The fourth session consists of a group walk.~Students will be monitored for 3 menstrual cycles. Starting from the end of the first menstrual period after completion of the training session, students will be asked to record their daily step count using a pedometer. In each menstrual period, the average of the students' monthly step count and average menstrual pain score will be evaluated. After the training sessions are completed, students will be given an end-of-menstrual motivational interview for 3 menstrual cycles.
Study: NCT06314932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD high in UPF
Description: A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MD high in UPF
Description: A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of UPF, as defined by the NOVA system (e.g., flavored yogurt, breakfast cereals with added sugar, processed meat).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD low in UPF
Description: A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MD low in UPF
Description: A 3-month dietary intervention with a Mediterranean diet with 5 servings/day of products from the same food group, but non-UPF (e.g., plain yogurt, breakfast cereals with no added sugar, unprocessed meat)
Study: NCT04703283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Medicine
Description: Lifestyle intervention with components including exercise, diet, stress management, and sleep management
Study: NCT05792293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 Mg Oral Tablet
Description: 40 mg oral dose of atorvastatin , lipid lowering drug with other pleotropic effects
Study: NCT04272372

Intervention type: DRUG
Intervention: Ketoprofen
Description: PO and local therapy

Intervention type: DRUG
Intervention: Ketoprofen
Description: PO and local therapy
Study: NCT05792293

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04600427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Description: T11-12 epidural blockade with 0.25% bupivacaine continuous infusion.
Study: NCT06193161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-supported internet delivered prolonged exposure
Description: Therapist-supported internet delivered prolonged exposure for eight weeks.
Study: NCT04098016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Intervention
Description: Participants will receive: 1) tailored behavior change goals, 2) self-monitoring with tailored feedback, 3) skills training.
Study: NCT05625516

Intervention type: DEVICE
Intervention: Bilateral external torque device
Description: The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent.

Intervention type: DEVICE
Intervention: Bilateral external torque device
Description: The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent.

Intervention type: DEVICE
Intervention: Bilateral external torque device
Description: The External Torque Device was developed, which allows bilateral stressing of the syndesmosis by external rotation. Both lower legs are stabilized by a special knee brace (the fibula remains free to float) or by the hip joints, which are end rotated on both sides, while an external rotation force of maximum 7.5Nm (or up to the respective pain threshold) can be set on both sides using torque newton meters. If no load is possible - which the examination of the syndesmosis generally does not allow - an intra-articular local anesthesia with 5ml ropivacaine 2mg/ml can be performed under sterile conditions after the patient's consent.
Study: NCT05376059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How Nudge
Description: We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How Nudge
Description: We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How Nudge
Description: We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How and Why Nudge
Description: We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How and Why Nudge
Description: We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How and Why Nudge
Description: We will nudge participants to get mental health treatment in a mailing that details how they can go about seeking treatment and why they should go about seeking treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive
Description: Participants in incentive groups will also receive a mailer that includes a an incentive to seek treatment (if they visit a therapist within 30 days, they will receive a gift card).
Study: NCT06381882

Intervention type: PROCEDURE
Intervention: Pancreatic resection
Description: Any kind of pancreatic resection will be included
Study: NCT05320224

Intervention type: OTHER
Group type: OTHER
Intervention: Patient-Oriented Music Intervention (POMI)
Description: The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).

Intervention type: OTHER
Group type: OTHER
Intervention: Patient-Oriented Music Intervention (POMI)
Description: The brief name given to this intervention is POMI (Patient-Oriented Music Intervention). In POMI, music is delivered to adult patients either via headphones (Bose) or by music pillow (MusiCure). Adults admitted to the intensive care unit (ICU) will choose the mode of delivery. ICU adult patients who are unable to self-report will hear music via music pillow. Individualized playlists will be created based on the patient music preferences, as self-reported. For patients unable to self-report, a person significant to the patient such as a family member will be asked about the patient music preferences. Questions about preferences will include music genre, track, artist, instrumentalness, acousticness, energy, and valence, as defined by the streaming service Spotify. A POMI web-based tool (https://pomi.glitch.me) will use these preferences to create personalized playlists on Spotify, with a tempo restriction of 60-80 bpm. Music will play for at least 20 minutes, via smart device (iPad).
Study: NCT05320289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AblaCare System
Description: The intervention includes the short-term use of the AblaCare System, which is comprised of three elements: (1) the AblaCare Needle-Catheter Ablation Device (NCAD) (the Device) a 16G echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secure onto a vaginal ultrasound probe; (2) the AblaCare Adapter which is clipped onto the ultrasound probe; and (3) the AblaCare Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use AblaCare NCAD for ovarian tissue ablation.~Once th patient is under conscious sedation, the physician guides the AblaCare system transvaginally with the use of a transvaginal ultrasound. Once the AblaCare device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
Study: NCT05792956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Using mobile app
Description: Women with OAB in this group will be informed about mobile application usage. The group using the mobile application will add the times they have consumed fluid and urine leakage to the bladder diary section of the mobile application. During the day, the application will remind participants to consume fluids and urinate. There will also be a question and answer section in the mobile application. Women will be able to direct their questions about OAB to the researcher. After the first meeting, the scales sent through the mobile application will be applied in the 3rd and 6th months.
Study: NCT04876417

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Transcranial Direct Current Stimulation is a form of non-invasive brain stimulation. It uses small electrodes to deliver small amounts of current to specific areas of the brain to either increase or decrease excitability.
Study: NCT04583228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX71
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX71
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX71
Description: Single-dose, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX71
Description: Single-dose, intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single-dose, intravenous infusion
Study: NCT05843344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block with a combination of ropivacaine and morphine
Description: Before surgery, a US guided ESPB will be performed, and a catheter will be placed. Serratus Anterior Plane Block (SAPB) will be also performed without catheter placement. 20 mL of Ropivacaine 0.375% will be injected in the SAPB. In this group, 19 mL of 0.375% Ropivacaine + 2 mg (1mL) of morphine will be injected in the ESPB. Continuous peripheral nerve catheters will be placed for postoperative analgesia under the Erector Spinae muscle. A pump of 497 ml of 0.2 % ropivacaine + 6 mg of morphine (contained in 3 mL) will be connected to the catheter after the end of the surgery, and the continuous dose will be 10 mL/hr